U.S. Stock Insider Trading | Lexeo Therapeutics disclosed two insider transactions on March 17

K-LinePoet · 2026-04-03T07:43:06+00:00

On March 17, 2026, Lexeo Therapeutics disclosed insider trading activities by executives and directors. Executive Otero purchased 5,930 shares on March 13, and Director Townsend bought 2,623 shares. The company is a clinical-stage firm focused on gene medicine, dedicated to transforming disease treatment.

K-LinePoet

2026-04-03 07:43:06

Abstract generation in progress

On March 17, 2026, Lexeo Therapeutics (LXEO) disclosed two transactions involving company insiders. On March 13, 2026, executive Otero Jose Manuel purchased 5,930 shares.

【Recent Insider Trading】

Disclosure date	Position	Name	Transaction date	Buy/Sell	Quantity	Price per share/USD	Total amount/USD
March 17, 2026	Executive	Otero Jose Manuel	March 13, 2026	Buy	5930	2.64	15.7k
March 17, 2026	Director	Townsend Richard Nolan	March 13, 2026	Buy	2623	2.64	6935.21
February 20, 2026	Executive	Otero Jose Manuel	February 18, 2026	Sell	3016	6.40	19.3k
February 20, 2026	Director	Townsend Richard Nolan	February 18, 2026	Sell	10.2k	6.38	64.9k
February 20, 2026	Executive	Otero Jose Manuel	November 18, 2025	Sell	721	9.27	6683.67
November 20, 2025	Executive	Adler Eric	November 18, 2025	Sell	615	9.27	5701.05
November 20, 2025	Executive	See Tai Sandi	November 18, 2025	Sell	386	9.27	3578.22
November 20, 2025	Director	Townsend Richard Nolan	November 18, 2025	Sell	1127	9.27	10.4k
November 20, 2025	Executive	Robertson Jenny	November 18, 2025	Sell	549	9.27	5089.23
October 17, 2025	Executive	Robertson Jenny	October 17, 2025	Sell	3486	8.94	31.1k

【Company Profile】

Lexeo Therapeutics, Inc. was formed on February 17, 2017, as a limited liability company under the laws of the State of Delaware, with the legal name Lexeo Therapeutics, LLC. On November 20, 2020, the company converted the limited liability company into Lexeo Therapeutics, Inc. in Delaware. The company is a clinical-stage gene medicine company, dedicated to transforming healthcare by fundamentally changing the way diseases are treated through the application of pioneering science. Its most advanced cardiovascular candidate product, LX2006, is used to treat patients with cardiomyopathy suffering from Friedreich’s ataxia (abbreviated as FA); it is currently conducting an ongoing Phase 1/2 clinical trial. The company’s second most advanced cardiovascular candidate product, LX2020, is used to treat arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene, abbreviated as PKP2-ACM. In July 2023, it received IND approval from the U.S. Food and Drug Administration (FDA).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.